Joseph Feldschuh, President & CEO of Daxor Corporation, bought 1,500 shares of Daxor Corporation (Stock Symbol: Enter DXR) at $7 per share for a total amount of $10.5 thousand on March, 5th 2014.
Daxor Corporation is headquartered in New York, New York.
On 02/28/2014, Daxor Corporation an investment company with medical instrumentation and biotechnology operations, will be filing a Form N-CSR today disclosing its schedule of portfolio holdings as of December 31, 2013. Copies of the form will be mailed to the Company’s shareholders and are available on the Company’s website at http://www.daxor.com/pdfs/daxor-form-n-csr-12312013.pdf.
On 11/15/2013, Daxor Corporation an investment company with medical instrumentation and biotechnology operations, announced the payment of a dividend today.
The Board of Directors has approved payment of a dividend of $0.05 per share. The dividend will be paid on Friday, December 27th to shareholders of record on Monday, December 9th.
According to Capital IQ, Daxor Corporation has a market cap of $32.71 million, an enterprise value of $52.96 million.
Daxor Corporation is a medical device manufacturing company which provides additional biotechnology services. The Company focuses on the creation and development of the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume. This instrument is used in conjunction with Volumex , a single-use radiopharmaceutical diagnostic injection and collection kit. The Company also offers cryobanking services for blood storage through Scientific Medical Systems and for semen storage through Idant, a subsidiary of Scientific Medical Systems. The Company also owns the Daxor Oak Ridge Operations (DORO) facility in Oak Ridge, Tennessee, which manufactures, tests, and develops next-generation models of the BVA-100. In March 2013, Banner Good Samaritan Medical Center of Phoenix, Arizona purchased a BVA-100 Blood Volume Analyzer.
Joseph Feldschuh’s most recent annual compensation from Daxor Corporation is a salary of $325,000, $13,406 in other compensation, and a total compensation of $338,406. Mr. Last Name is 77 years old.
According to his biography, Dr. Joseph Feldschuh, M.D., is Chairman of the Board, President of Daxor Corp. He is on the staff of Montefiore Medical Center. From 1966 to 1983, Dr. Feldschuh was Director of the Cardiac Metabolic Laboratory at Metropolitan Hospital. He has been a Clinical Associate Professor in both medicine and pathology at New York Medical College and an Assistant Clinical Professor at Cornell Medical School. He performed the basic research at the College of Physicians and Surgeons (Columbia University) on the measurement and prediction of normal human blood volume. He is the co-inventor of the BVA-100 Blood Volume Analyzer and the inventor of the quantitative injection kit for the BVA-100. Originally trained in Endocrinology, he is Board Certified in Cardiology and Internal Medicine. Dr. Feldschuh is the Chief Scientist for the Company. He has been personally involved in measuring blood volume on more than 4,000 patients during his medical career. In addition to his duties as Chief Scientist of Daxor, Dr. Feldschuh is also responsible for managing the Company’s investment portfolio.
All stories in DailyStocks.com are for informational purposes only. This is NOT a stock recommendation. This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com .
About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.